Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer
Recruiting
Phase 1
Phase 2
Interventional Study
Cervical Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 75
- Sex
- Female
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 120 (estimated)
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a multicenter, open-label phase I/II study in patients with advanced cervical cancer designed to evaluate the safety, tolerability, and preliminary efficacy of ZG005 in combination with Gecacitinib ± bevacizumab.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Fully understand the study and voluntarily sign the informed consent form.
* Female 18-75 years of age;
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
* Histologically or cytologically confirmed advanced cervical cancer, including squamous cell carci…
Contacts